TL-532, a novel rationally designed TLR3 agonist, induces tumor-specific apoptosis, immune simulation, life-long anti-tumor auto-vaccination, and reverses resistance to immune checkpoint inhibitors
OTS – October 2022, Phoenix (USA) – M Bonnin
TL-532 specific TLR3 agonist induces lifelong anti-tumor autovaccination, cross-immunity against unrelated cancer and reverses resistance to immune checkpoint inhibitors
IRCI 15-17 June 2022 Lyon – M Bonnin
TL-532 specific TLR3 agonist induces lifelong anti-tumor autovaccination, cross-immunity against unrelated cancer and reverses resistance to immune checkpoint inhibitors
AACR 8-13 Avril 2022 New Orleans – S Thierry
Synthetic TLR-3 ligands
ESMO – December 2021 – Presented by Dr Bettina Werle
Discovery process and in vitrobiological characterization of rationally designed TL-532 Toll-like Receptor 3 (TLR3) agonist as anti-cancer molecule
OTS – September 2021 – Dr Marc Bonnin
First Rationally Designed TLR3 Agonist “TL-532”Induces Tumor Specific Apoptosis, Microenvironment Switch and Immune Stimulation, Leading to Life-long Anti-tumor Auto-vaccination
OTS – September 2021 – Dr Sylvain Thierry
Recent Comments